News

How GLP-1 drugs like semaglutide have revolutionised obesity treatment
Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide — are now available in the Indian market. Here’s how they work, how ...
Fierce Pharma2d
With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs
In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...
BioSpace2d
Altimmune Nosedives on Mixed Mid-Stage MASH Data for GLP-1/Glucagon Drug
Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval From China's NMPA For Chronic Weight Management
The increasing prevalence of overweight and obesity in China poses an urgent public health challenge requiring immediate ...
Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide
Altimmune, Inc.'s pemvidutide shows promising results in MASH resolution and weight loss, paving the way for phase 3 trials.
Fierce Biotech3d
Altimmune's stock sinks on mixed phase 2 MASH results for GLP-1 drug
Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
About the IMPACT Study The IMPACT (NCT05989711) trial enrolled 212 patients with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes randomized 1:2:2 to receive either weekly ...
The Malaysian Reserve4d
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ ...
Sarcopenia Market To Register Sustainable Growth At A CAGR Of 8.1% During The Study Period (2020-2034) Delveinsight
The sarcopenia market size shall grow during the forecast period (2025–2034) due to the launch of upcoming therapies and the increasing cases ...